Patrick Floody

Senior Director, Global Study Strategy & Optimization, Regeneron

Patrick has over 26 years’ experience in new drug development. He joined Regeneron in March 2020 as the Head of the Global Study Strategy & Optimization group, responsible for study feasibility and site selection, study/site start up and eCOA and patient technology initiatives.

Prior to this, Patrick spent 25 years at Pfizer. He joined in 1995 as a CRA working on one of the first oncology drugs developed by Pfizer. Most of his career has been spent in clinical program operations but also includes GCP Quality (level 1) and Analytics. During his career, he has focused on continuous improvement in all aspects of drug development operations.

Patrick has extensive international experience in drug development. In the late 1990’s, he joined Pfizer’s International Clinical Research Group where he helped establish the country office development teams in Latin America, India and other parts of Asia, including extended stays in Argentina and Mexico. Subsequently, Patrick spent 10 years in Pfizer’s Development Japan organization as Head of Japan Development Operations and Development Japan Portfolio & Project Management Groups.

In 2012, Patrick repatriated as the Pfizer’s Development Asset Group Lead for Specialty Care Business Unit and Primary Care Business Unit. Patrick has worked across many therapeutic areas including cardiovascular & metabolic diseases, oncology, urology, rare diseases, anti-infectives and woman’s health. He was the recipient of the PGRD Achievement Award in 2007.

Patrick is a former officer in the U.S. Army and is a veteran of the first Gulf War. He holds a bachelor’s degree in Biology from the University of Rhode Island and a Master of Business Administration from Temple University.